CD38 and Miyoshi myopathy: Recent additions approved in MM after ≥4 lines of prior therapies (including an IMiD, a PI and an anti‐CD38 mAb), include CAR‐T agents idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel, and the anti‐BMCA ADC belantamab mafodotin.